Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study

K-H YuDivision of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC

J-H LaiDivision of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University and School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC

P-N HsuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ROC

D-Y ChenFaculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC;Department of Medical Education and Research, Taichung Veterans General Hospital, Taichung, Taiwan, ROC;Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan, ROC;Institute of Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan, ROC

C-J ChenDepartment of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC

H-Y LinDivision of Allergy, Immunology and Rheumatology, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC;Taipei Medical University, School of Medicine, Taipei, Taiwan, ROCCorrespondence[email protected]

Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date